Sei Investments Co. Has $758,000 Stake in Lumexa Imaging Holdings, Inc. $LMRI

Sei Investments Co. grew its position in Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI) by 339.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 88,190 shares of the company’s stock after purchasing an additional 68,127 shares during the quarter. Sei Investments Co.’s holdings in Lumexa Imaging were worth $758,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the company. T. Rowe Price Investment Management Inc. bought a new position in Lumexa Imaging during the fourth quarter worth $37,139,000. Janus Henderson Group PLC bought a new stake in Lumexa Imaging during the fourth quarter valued at $36,860,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Lumexa Imaging during the 4th quarter worth about $27,750,000. ArrowMark Colorado Holdings LLC acquired a new stake in Lumexa Imaging during the 4th quarter worth about $27,750,000. Finally, Invesco Ltd. bought a new position in shares of Lumexa Imaging in the 4th quarter worth about $26,562,000.

Lumexa Imaging Trading Up 4.0%

LMRI opened at $12.20 on Friday. The company has a fifty day moving average price of $10.78 and a two-hundred day moving average price of $10.90. Lumexa Imaging Holdings, Inc. has a 1-year low of $6.45 and a 1-year high of $19.45. The company has a market cap of $1.17 billion and a P/E ratio of -20.68. The company has a current ratio of 1.40, a quick ratio of 1.40 and a debt-to-equity ratio of 1.43.

Insider Activity at Lumexa Imaging

In other news, Director Brett Brodnax bought 35,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 19th. The stock was acquired at an average cost of $7.25 per share, with a total value of $253,750.00. Following the transaction, the director directly owned 62,027 shares of the company’s stock, valued at approximately $449,695.75. This represents a 129.50% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.70% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

LMRI has been the topic of several research analyst reports. Barclays cut their target price on Lumexa Imaging from $15.00 to $9.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 20th. Weiss Ratings upgraded Lumexa Imaging from a “sell (e)” rating to a “sell (d)” rating in a report on Thursday, June 25th. Deutsche Bank Aktiengesellschaft set a $16.00 price target on Lumexa Imaging in a research note on Thursday. Finally, Wall Street Zen downgraded shares of Lumexa Imaging from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Lumexa Imaging Profile

We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).